STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

OGEN Form 3: Natasha Giordano Listed as Director, Zero Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Oragenics Inc. reporting person Natasha Giordano filed an Initial Statement of Beneficial Ownership (Form 3) related to a 09/01/2025 event. The filing lists Giordano's address in Sarasota, FL and indicates her relationship to the issuer as a Director. The form states no securities are beneficially owned by Giordano as of the filing. The document is signed by an attorney-in-fact on behalf of Giordano on 09/02/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Form 3 discloses a new director relationship with no reported ownership, a neutral governance disclosure with limited market impact.

The filing records Natasha Giordano as a director of Oragenics Inc. and explicitly reports zero beneficial ownership of the issuer's securities. For investors, a Form 3 that shows no holdings means there is currently no insider-equity alignment disclosed in this filing; it provides transparency about the reporting person's status but contains no financial metrics or transactions to affect valuation.

TL;DR: Disclosure confirms director status without equity stake; routine compliance filing, not materially informative for governance change analysis.

The document fulfills Section 16 reporting requirements by identifying Giordano and her role as a director, the event date 09/01/2025, and the absence of beneficial ownership. The signature by an attorney-in-fact on 09/02/2025 completes procedural formality. This filing alone does not indicate share acquisitions, related-party transactions, or compensation arrangements.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Giordano Natasha

(Last) (First) (Middle)
1990 MAIN STREET, SUITE 750

(Street)
SARASOTA FL 34236

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2025
3. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Julio C. Esquivel as Attorney-In-Fact for Natasha Giordano 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Oragenics (OGEN) Form 3 filed for Natasha Giordano disclose?

The Form 3 discloses that Natasha Giordano is reported as a Director of Oragenics Inc. and that she owns no beneficial securities as of the filing.

When is the event date and when was the Form 3 signed for OGEN's filing?

The event requiring the statement is dated 09/01/2025, and the form is signed on behalf of Natasha Giordano by an attorney-in-fact on 09/02/2025.

Does the Form 3 show any stock options or derivative holdings for Natasha Giordano at OGEN?

No. Table I and Table II in the filing indicate no securities are beneficially owned, and no derivative or option positions are reported.

What address is listed for the reporting person on the OGEN Form 3?

The address listed for Natasha Giordano is 1990 Main Street, Suite 750, Sarasota, FL 34236.

Is this Form 3 an individual filing or filed on behalf of multiple reporting persons?

The filing indicates it is a Form filed by one reporting person.
Oragenics

NYSE:OGEN

OGEN Rankings

OGEN Latest News

OGEN Latest SEC Filings

OGEN Stock Data

3.88M
4.07M
2.41%
2.56%
0.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
SARASOTA